Advertisement
YOU ARE HERE: LAT HomeCollectionsRorer Group Inc
IN THE NEWS

Rorer Group Inc

FEATURED ARTICLES
ARTICLES BY DATE
Advertisement
BUSINESS
March 13, 1990 | LINDA WILLIAMS, TIMES STAFF WRITER
Rhone-Poulenc SA, France's largest pharmaceuticals company, signed an agreement Monday to buy a majority interest in Ft. Washington, Pa.-based Rorer Group and merge its human drug business with Rorer to create one of the world's 10 largest drug companies. Analysts said the two-step transaction--including the issuance of special new rights to all Rorer shareholders--puts a value of $3.2 billion, or $73 a share, on the merger.
BUSINESS
January 19, 1990 | From Reuters
Rhone-Poulenc S.A., a giant French chemical firm, agreed on Thursday to acquire Rorer Group Inc., in a deal valuing the American drug company at $3.2 billion, the companies said. The newly combined company will be one of the top 10 pharmaceutical companies in the world. It will be led by Robert Cawthorn, who is Rorer's chairman, president and chief executive, the companies said.
BUSINESS
January 19, 1990 | Reuters
The Securities and Exchange Commission has sued three overseas entities and a Swiss investor for insider trading in shares of pharmaceuticals group Rorer Group Inc. The company said Monday that it is in merger talks with an unidentified suitor, news that sent the stock sharply higher. In a suit filed late Wednesday, the SEC accused Fondation Hai of Monaco; Holding Protection Ltd.
BUSINESS
January 8, 1988 | Associated Press
Sanofi S.A. officials said Thursday that they were willing to boost the value of their company's offer to merge with A. H. Robins Co. if necessary to beat out other suitors for the pharmaceutical giant. Separately, the committee representing Robins' shareholders in the company's Chapter 11 bankruptcy reorganization indicated that it was continuing negotiations with all three suitors and hoped to endorse a plan on Friday.
BUSINESS
September 4, 1986 | ROBERT HANLEY, Times Staff Writer
Acting on rumors of a takeover bid by Costa Mesa-based ICN Pharmaceuticals Inc., speculators boosted shares of the Rorer Group Inc. by $3.875 Wednesday to a closing price on the New York Stock Exchange at $43.75 a share. With more than 3.5 million shares traded, the Fort Washington, Penn., drug firm was the Big Board's third-most active issue Wednesday. Securities analysts said a merger could be possible, given recent statements by ICN that it plans to make a major acquisition.
BUSINESS
January 19, 1990 | From Reuters
Rhone-Poulenc S.A., a giant French chemical firm, agreed on Thursday to acquire Rorer Group Inc., in a deal valuing the American drug company at $3.2 billion, the companies said. The newly combined company will be one of the top 10 pharmaceutical companies in the world. It will be led by Robert Cawthorn, who is Rorer's chairman, president and chief executive, the companies said.
BUSINESS
January 19, 1990 | Reuters
The Securities and Exchange Commission has sued three overseas entities and a Swiss investor for insider trading in shares of pharmaceuticals group Rorer Group Inc. The company said Monday that it is in merger talks with an unidentified suitor, news that sent the stock sharply higher. In a suit filed late Wednesday, the SEC accused Fondation Hai of Monaco; Holding Protection Ltd.
BUSINESS
January 8, 1988 | Associated Press
Sanofi S.A. officials said Thursday that they were willing to boost the value of their company's offer to merge with A. H. Robins Co. if necessary to beat out other suitors for the pharmaceutical giant. Separately, the committee representing Robins' shareholders in the company's Chapter 11 bankruptcy reorganization indicated that it was continuing negotiations with all three suitors and hoped to endorse a plan on Friday.
BUSINESS
January 6, 1988 | JAMES FLANIGAN
A. H. Robins Co., the pharmaceutical company facing almost 200,000 claims of injury because of the Dalkon Shield birth control device, will go into a bankruptcy court in Richmond, Va., today and choose one of the three corporate suitors willing to pay $3.1 billion or more for the company.
BUSINESS
January 4, 1988 | From Times Wire Services
A. H. Robins Co.'s acceptance of a merger offer from French drug company Sanofi S.A. drew a hostile reaction over the weekend from the committee representing victims of the Dalkon Shield intrauterine contraceptive device and from the losing suitors in the three-way bidding war. And an attorney representing outside shareholders of the Richmond, Va.-based pharmaceutical company said he is still evaluating the French offer.
BUSINESS
January 4, 1988 | From Times Wire Services
A. H. Robins Co.'s acceptance of a merger offer from French drug company Sanofi S.A. drew a hostile reaction over the weekend from the committee representing victims of the Dalkon Shield intrauterine contraceptive device and from the losing suitors in the three-way bidding war. And an attorney representing outside shareholders of the Richmond, Va.-based pharmaceutical company said he is still evaluating the French offer.
NEWS
July 4, 1987 | JONATHAN PETERSON and JESUS SANCHEZ, Times Staff Writers
In a move that could settle millions of dollars in damage claims related to the Dalkon Shield contraceptive, beleaguered A.H. Robins Co. said Friday that it planned to merge with the Rorer Group Inc. in a deal they valued at $2.6 billion. The agreement between the pharmaceutical companies would clear the way for thousands of women to be compensated for injuries that they say they suffered from using the intrauterine device.
NEWS
December 12, 1987 | JONATHAN PETERSON, Times Staff Writer
The company that marketed Dalkon Shield contraceptive devices must set aside $2.47 billion to pay off thousands of remaining injury claims, a federal judge said Friday in a two-minute announcement that could settle a lengthy and bitter legal wrangle dating back to the product's use in the early 1970s. The finding, which comes more than two years after A. H. Robins Co.
Los Angeles Times Articles
|